Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside

Autor: Mounia Sabrina Braza, Bernard Klein
Přispěvatelé: Cellules souches normales et cancéreuses, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Institut de recherche en biothérapie (IRB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Université Montpellier 1 - UFR de Médecine (UM1 Médecine), Université Montpellier 1 (UM1), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Frei, Monique
Jazyk: angličtina
Rok vydání: 2013
Předmět:
Receptors
Antigen
T-Cell
alpha-beta
medicine.medical_treatment
Lymphocyte
MESH: Antigens
Neoplasm
MESH: Translational Medical Research
MESH: Adjuvants
Immunologic
MESH: T-Lymphocyte Subsets
Adaptive Immunity
CD8-Positive T-Lymphocytes
Immunotherapy
Adoptive
T-Lymphocytes
Regulatory
Translational Research
Biomedical
0302 clinical medicine
Cancer immunotherapy
T-Lymphocyte Subsets
Neoplasms
MESH: Neoplasms
Immunologic Surveillance
Cells
Cultured
Clinical Trials as Topic
0303 health sciences
MESH: Receptors
Antigen
T-Cell
alpha-beta
Diphosphonates
MESH: Dendritic Cells
Gene Rearrangement
gamma-Chain T-Cell Antigen Receptor
Receptors
Antigen
T-Cell
gamma-delta
Hematology
Acquired immune system
MESH: Gene Rearrangement
delta-Chain T-Cell Antigen Receptor
MESH: CD8-Positive T-Lymphocytes
3. Good health
Killer Cells
Natural
medicine.anatomical_structure
MESH: Immunotherapy
Adoptive
MESH: Tumor Escape
[SDV.IMM]Life Sciences [q-bio]/Immunology
MESH: Immunity
Innate
immunotherapy
monoclonal antibodies
MESH: Cells
Cultured
MESH: Killer Cells
Natural
[SDV.IMM] Life Sciences [q-bio]/Immunology
MESH: Clinical Trials as Topic
MESH: Diphosphonates
T cell
Gene Rearrangement
delta-Chain T-Cell Antigen Receptor
haematological oncology
03 medical and health sciences
Adjuvants
Immunologic
Antigen
Antigens
Neoplasm
gamma delta T lymphocytes
MESH: Receptors
Antigen
T-Cell
gamma-delta
medicine
Humans
cancer
030304 developmental biology
MESH: Immunologic Surveillance
MESH: Humans
business.industry
MESH: T-Lymphocytes
Regulatory
Mesenchymal Stem Cells
Dendritic Cells
Immunotherapy
Gene rearrangement
T lymphocyte
Immunity
Innate
MESH: Gene Rearrangement
gamma-Chain T-Cell Antigen Receptor
Immunology
MESH: Mesenchymal Stromal Cells
Tumor Escape
business
MESH: T-Lymphocytes
Cytotoxic
MESH: Adaptive Immunity
T-Lymphocytes
Cytotoxic
030215 immunology
Zdroj: British Journal of Haematology
British Journal of Haematology, Wiley, 2013, 160 (2), pp.123-32. ⟨10.1111/bjh.12090⟩
ISSN: 0007-1048
1365-2141
DOI: 10.1111/bjh.12090⟩
Popis: International audience; Gamma delta (γδ) Τ cells are non-conventional T lymphocyte effectors that can interact with and eradicate tumour cells. Several data demonstrate that these T cells, which are implicated in the first line of defence against pathogens, have anti-tumour activity against many cancers and suggest that γδ Τ cell-mediated immunotherapy is feasible and might induce objective tumour responses. Due to the importance of γδ Τ lymphocytes in the induction and control of immunity, a complete understanding of their biology is crucial for the development of a potent cancer immunotherapy. This review discusses recent advances in γδ Τ basic research and data from clinical trials on the use of γδ Τ cells in the treatment of different cancers. It analyses how this knowledge might be applied to develop new strategies for the clinical manipulation and the potentiation of γδ Τ lymphocyte activity in cancer immunotherapy.
Databáze: OpenAIRE
Externí odkaz: